114 results
Page 2 of 6
6-K
EX-99.1
ykv pvykaqlyg
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
2j92a7r16z84swi06equ
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
wmujt2qin5
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
urfm893 ugkdd8a0
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
F-3
EX-4.1
wezaqemyysn97
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
jy3q2dpseua j5b2c
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
yy1ts4jesre5e03swhz4
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
s4ne52z9
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
EX-99.3
om7u1jsij
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.1
3jnit
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
rgbyoy6p7cwt5y6un3c
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
a8m144aj3xv3lmqbz7
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
EX-99.1
g6zjsffd2alcma
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.2
hwquwbc8
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
kg7d1lt2ig2pz4cco
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.2
sfiox2tfy
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.1
47yo3uqlv 59fe
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K/A
EX-99.2
a9frlvxrfcz 89y6kc5
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm